Ibere Pharmaceuticals
| IPO Proceeds, $M | $138.00M |
|---|---|
| IPO Date | Feb 26, 2021 |
| CEO | Osagie Imasogie |
| Left Lead | Raymond James |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector | Healthcare |
| IPO Geography | Global |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
| Closing Date | Mar 2, 2023 |
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
No credit card required
Sign in for more on Ibere Pharmaceuticals:
- Structure and cap table
- 7 directors & officers
- 7 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Osagie Imasogie | 59 | Chairman, Chief Executive Officer and Director |
| Lisa Gray | 56 | Chief Financial Officer, Executive Vice President and Director |
| Zoltan Kerekes | 55 | Chief Operating Officer, Executive Vice President and Director |
| Louis J. Vollmer | 64 | Director |
| Elaine V. Jones | 66 | Director |
| Henrietta Ukwu | 61 | Director |
| Calvin B. Johnson | 54 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
| Raymond James | BR | 12,000,000 | units |
| 12,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Filings
| Feb 8, 2021 | Initial S-1 |
| Feb 22, 2021 |
S-1/A Amendment #1
Sign In to view filing content. |
| Feb 26, 2021 |
PR announcing pricing of $120mm upsized IPO
Sign In to view filing content. |
| Mar 1, 2021 | 424B4 IPO Prospectus |
| Mar 3, 2021 |
8-K announcing full over-allotment exercise
Sign In to view filing content. |
| Aug 4, 2021 |
8-K announcing change in certifying accountant
Sign In to view filing content. |
| Feb 15, 2023 |
8-K announcing liquidation and redemption of all public shares
Sign In to view filing content. |